重组人白介素-11治疗化疗所致血小板减少的临床观察  

Clinical research of recombinant human interleukin-11 therapy for chemotherapy induced thrombocytopenia

作　　者：张建华[1] 严晓春[1] 吴云[1] 

机构地区：[1]淮安市肿瘤医院肿瘤内科,江苏淮安223200

出　　处：《临床肿瘤学杂志》2009年第5期452-453,共2页Chinese Clinical Oncology

摘　　要：目的:观察重组人白介素-11(rhIL-11)对恶性肿瘤患者因化疗所致血小板减少的疗效及毒副反应。方法:化疗后血小板低于25×109/L给予rhIL-11 50μg/(kg.d)皮下注射,血小板低于50×109/L给予rhIL-11 25μg/(kg.d)皮下注射,观察外周血小板变化,血小板升至≥75×109/L时停药。结果:血小板升至≥75×109/L所需时间:Ⅲ度22例(5.0±1.3)天,Ⅳ度8例(12.4±1.6)天。主要毒副反应为乏力、水肿、关节肌肉疼痛、注射部位疼痛。结论:重组人白介素-11(rhIL-11)有升高化疗后血小板减少的作用,毒副反应可耐受。Objective ：To observe the efficacy and side effects of recombinant human interleukin-11 （rhIL-11 ）in the treatment of thrombocytopenia caused by chemotherapy in patients with malignancies. Methods：Platelets after chemotherapy less than 30 × 10^9/L were injected subcutaneously with rhIL-11 501xg/（ kg.d）, platelets less than 50 × 10^9/L with rhIL-11 25μg/（kg·d） subcutaneous injection to observe changes in peripheral platelet until the counts of platelets came to 75 × 10^9/L. Results：Observed the time required to platelets increased to ≥75 × 10^9/L. The time to grade Ⅲ thrombocytopenia were（5.0 ± 1.3 ） days,and that of grade Ⅳ were（ 12.4 ±1.6） days. The main side effects including fatigue, edema,local pain of injection, arthralgia/muscular soreness. Conclusion： Recombinant human interleukin-11 （ rhIL-11 ） can elevate blood platelet count and a effective drug for treatment of thrombocytopenia caused by chemotherapy. Adverse reactions can be tolerated.

关 键 词：重组人白介素-11 化学治疗 血小板减少 

分 类 号：R730.53[医药卫生—肿瘤]